Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Canadian Cancer Trials Group
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Mayo Clinic
Institut Curie
City of Hope Medical Center
Boundless Bio, Inc.
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Transgene
Novartis
Hadassah Medical Organization
Valo Therapeutics Oy
Institut Bergonié
Numab Therapeutics AG
University of California, Irvine
NextPoint Therapeutics, Inc.
Esperas Pharma Inc.